Skip to content

JBIO JBIO Payment Of Deferred Offering Costs

Payment Of Deferred Offering Costs at other companies

Navan, Inc.
 logo
Navan, Inc. NAVN
$407K
Rigetti Computing, Inc. logo
Rigetti Computing, Inc.RGTI
$0-100%
NetSTREIT logo
NetSTREITNTST
$259K-20.0%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$252K+1,300%
ServiceTitan, Inc. logo
ServiceTitan, Inc.TTAN
$149.75K
BlackSky Technology logo
BlackSky TechnologyBKSY
$0-100%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept ck0001798749:PaymentOfDeferredOfferingCosts.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's payment of deferred offering costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's payment of deferred offering costs?
JBIO (JBIO) reported payment of deferred offering costs of $700K in Q1 2025.
What does payment of deferred offering costs mean?
This captures the cash outflows related to professional fees, legal expenses, and underwriting costs incurred in preparation for equity or debt offerings. These costs are typically deferred and then reclassified to equity upon the successful completion of the financing event. It serves as a measure of the capital-raising efficiency and the cost of accessing public markets.